{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:33:11Z","timestamp":1793313191553,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40272-023-00558-x","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:48:51Z","timestamp":1674276531000},"page":"135-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-5781","authenticated-orcid":false,"given":"Inmaculada","family":"Baeza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-0841","authenticated-orcid":false,"given":"Adriana","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-0331","authenticated-orcid":false,"given":"Daniel","family":"Ilzarbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2545-7862","authenticated-orcid":false,"given":"Gisela","family":"Sugranyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"558_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/eip.12412","volume":"11","author":"J Immonen","year":"2017","unstructured":"Immonen J, J\u00e4\u00e4skel\u00e4inen E, Korpela H, Miettunen J. Age at onset and the outcomes of schizophrenia: a systematic review and meta-analysis. Early Interv Psychiatry. 2017;11:453\u201360. https:\/\/doi.org\/10.1111\/eip.12412.","journal-title":"Early Interv Psychiatry"},{"key":"558_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40273-016-0444-6","volume":"35","author":"H Jin","year":"2017","unstructured":"Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics. 2017;35:25\u201342. https:\/\/doi.org\/10.1007\/s40273-016-0444-6.","journal-title":"Pharmacoeconomics"},{"key":"558_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.3405","author":"V Latorre","year":"2021","unstructured":"Latorre V, Messeni Petruzzelli A, Uva AE, Ranaudo C, Semisa D. Unveiling the actual cost of schizophrenia: an activity-based costing (ABC) approach. Int J Health Plann Manage. 2021. https:\/\/doi.org\/10.1002\/hpm.3405.","journal-title":"Int J Health Plann Manage"},{"key":"558_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jaac.2013.02.008","volume":"52","author":"J McClellan","year":"2013","unstructured":"McClellan J, Stock S. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013;52:976\u201390. https:\/\/doi.org\/10.1016\/j.jaac.2013.02.008.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"558_CR5","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1176\/ajp.151.10.1409","volume":"151","author":"JD Hegarty","year":"1994","unstructured":"Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409\u201316. https:\/\/doi.org\/10.1176\/ajp.151.10.1409.","journal-title":"Am J Psychiatry"},{"key":"558_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1192\/bjp.bp.108.060723","volume":"195","author":"TK Rajji","year":"2009","unstructured":"Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2009;195:286\u201393. https:\/\/doi.org\/10.1192\/bjp.bp.108.060723.","journal-title":"Br J Psychiatry"},{"key":"558_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.chc.2019.08.008","volume":"29","author":"PD Harvey","year":"2020","unstructured":"Harvey PD, Isner EC. Cognition, social cognition, and functional capacity in early-onset schizophrenia. Child Adolesc Psychiatr Clin N Am. 2020;29:171\u201382. https:\/\/doi.org\/10.1016\/j.chc.2019.08.008.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"558_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/YCO.0b013e32833b027e","volume":"23","author":"AK Mattai","year":"2010","unstructured":"Mattai AK, Hill JL, Lenroot RK. Treatment of early-onset schizophrenia. Curr Opin Psychiatry. 2010;23:304\u201310. https:\/\/doi.org\/10.1097\/YCO.0b013e32833b027e.","journal-title":"Curr Opin Psychiatry"},{"key":"558_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40263-015-0308-1","volume":"30","author":"RC Harvey","year":"2016","unstructured":"Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs. 2016;30:27\u201339. https:\/\/doi.org\/10.1007\/s40263-015-0308-1.","journal-title":"CNS Drugs"},{"key":"558_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","volume":"56","author":"AK Pagsberg","year":"2017","unstructured":"Pagsberg AK, Tarp S, Glintborg D, Stenstr\u00f8m AD, Fink-Jensen A, Correll CU, et al. Acute antipsychotic treatment in children and adolescents with schizophrenia spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017;56:191\u2013202. https:\/\/doi.org\/10.1016\/j.jaac.2016.12.013.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"558_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","volume":"28","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol. 2018;28:659\u201374. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.008.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"558_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","volume":"9","author":"A Semahegn","year":"2020","unstructured":"Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1):17. https:\/\/doi.org\/10.1186\/s13643-020-1274-3.","journal-title":"Syst Rev"},{"key":"558_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","volume":"225","author":"KV Sendt","year":"2015","unstructured":"Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225:14\u201330. https:\/\/doi.org\/10.1016\/j.psychres.2014.11.002.","journal-title":"Psychiatry Res"},{"key":"558_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","volume":"36","author":"S Garc\u00eda","year":"2016","unstructured":"Garc\u00eda S, Mart\u00ednez-Cengotitabengoa M, L\u00f3pez-Zurbano S, Zorrilla I, L\u00f3pez P, Vieta E, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36:355\u201371. https:\/\/doi.org\/10.1097\/JCP.0000000000000523.","journal-title":"J Clin Psychopharmacol"},{"key":"558_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","volume":"5","author":"PM Haddad","year":"2014","unstructured":"Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43\u201362. https:\/\/doi.org\/10.2147\/PROM.S42735.","journal-title":"Patient Relat Outcome Meas."},{"key":"558_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1586\/14737175.2013.811984","volume":"13","author":"L Citrome","year":"2013","unstructured":"Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13:767\u201383.","journal-title":"Expert Rev Neurother"},{"key":"558_CR17","unstructured":"NICE, 2014. Psychosis and Schizophrenia in Adults. The National Institute for Health and Clinical Excellence Guideline on Treatment and Management [WWW Document]. URL http:\/\/www.nice.org.uk\/guidance\/cg178\/"},{"key":"558_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/eip.13202","author":"L Lian","year":"2021","unstructured":"Lian L, Kim DD, Procyshyn RM, Fredrikson DH, C\u00e1zares D, Honer WG, et al. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: a systematic review and meta-analysis. Early Interv Psychiatry. 2021. https:\/\/doi.org\/10.1111\/eip.13202.","journal-title":"Early Interv Psychiatry"},{"key":"558_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/NDT.S88632","volume":"12","author":"C Montemagni","year":"2016","unstructured":"Montemagni C, Frieri T, Rocca P. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat. 2016;12:917\u201329. https:\/\/doi.org\/10.2147\/NDT.S88632.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"558_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/0004867419837358","volume":"53","author":"AT Olagunju","year":"2019","unstructured":"Olagunju AT, Clark SR, Baune BT. Long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome. Aust N Z J Psychiatry. 2019;53:509\u201327. https:\/\/doi.org\/10.1177\/0004867419837358.","journal-title":"Aust N Z J Psychiatry"},{"key":"558_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanz\u00e1-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4:198\u2013219. https:\/\/doi.org\/10.1177\/2045125314540297.","journal-title":"Ther Adv Psychopharmacol"},{"key":"558_CR22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171\u201380. https:\/\/doi.org\/10.2147\/PPA.S53795.","journal-title":"Patient Prefer Adherence"},{"key":"558_CR23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4088\/JCP.13r08440","volume":"74","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. J Clin Psychiatry. 2013;74:957\u201365.","journal-title":"J Clin Psychiatry"},{"issue":"127","key":"558_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","volume":"2011","author":"C Leucht","year":"2011","unstructured":"Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;2011(127):83\u201392. https:\/\/doi.org\/10.1016\/j.schres.2010.11.020.","journal-title":"Schizophr Res"},{"key":"558_CR25","unstructured":"Grupo de trabajo del CIBERSAM para la elaboraci\u00f3n de una gu\u00eda cl\u00ednica y terap\u00e9utica para primeros episodios psic\u00f3ticos. Gu\u00eda cl\u00ednica y terap\u00e9utica para primeros episodios psic\u00f3ticos en la infancia y la adolescencia. Informe de consenso de recomendaciones. Centro de Investigaci\u00f3n Biom\u00e9dica en Red-CIBER 2015. https:\/\/www.ciberisciii.es\/ficheros\/SAM\/Gu%C3%ADaPEPinfanciaAdolescencia_v5.0.pdf"},{"key":"558_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.chc.2013.04.001.Childhood","volume":"22","author":"DI Driver","year":"2013","unstructured":"Driver DI, Gogtay N, Rapoport JL. Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2013;22:539\u201355. https:\/\/doi.org\/10.1016\/j.chc.2013.04.001.Childhood.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"558_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1708\/2342.25114","volume":"51","author":"C Carlone","year":"2016","unstructured":"Carlone C, Pompili E, Silvestrini C, Nicol\u00f2 G. Aripiprazole once-monthly as treatment for psychosis in Turner syndrome: literature review and case report. Riv Psichiatr. 2016;51:129\u201334. https:\/\/doi.org\/10.1708\/2342.25114.","journal-title":"Riv Psichiatr"},{"key":"558_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/cap.2017.0096","volume":"28","author":"A Fortea","year":"2018","unstructured":"Fortea A, Ilzarbe D, Espinosa L, Solerdelcoll M, de Castro C, Oriolo G, et al. Long-acting injectable atypical antipsychotic use in adolescents: an observational study. J Child Adolesc Psychopharmacol. 2018;28:252\u20137. https:\/\/doi.org\/10.1089\/cap.2017.0096.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"558_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1089\/cap.2011.0035","volume":"21","author":"JL Kowalski","year":"2011","unstructured":"Kowalski JL, Wink LK, Blankenship K, Habenicht CD, Erickson CA, Stigler KA, et al. Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21:491\u20133. https:\/\/doi.org\/10.1089\/cap.2011.0035.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"558_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/bmj.1.6064.835-c","volume":"1","author":"MS Perinpanayagam","year":"1977","unstructured":"Perinpanayagam MS, Haig RA. Use of depot tranquillisers in disturbed adolescent girls. Br Med J. 1977;1:835\u20136.","journal-title":"Br Med J"},{"key":"558_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.9758\/cpn.2014.12.1.65","volume":"12","author":"H Umehara","year":"2014","unstructured":"Umehara H, Iga J, Ohmori T. Successful treatment of anorexia nervosa in a 10-year-old boy with risperidone long-acting injection. Clin Psychopharmacol Neurosci. 2014;12:65\u20136.","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"558_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/cap.2016.0055","volume":"27","author":"S Lytle","year":"2017","unstructured":"Lytle S, McVoy M, Sajatovic M. Long-acting injectable antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27:2\u20139. https:\/\/doi.org\/10.1089\/cap.2016.0055.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"558_CR33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178\u201389. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.03.001.","journal-title":"J Clin Epidemiol"},{"key":"558_CR34","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2013; https :\/\/www.ohri.ca\/programs\/clini cal_epide miolo gy\/oxfor d.asp. Accessed 22 April 2022."},{"key":"558_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-020-01582-9","author":"M Pozzi","year":"2020","unstructured":"Pozzi M, Ferrentino RI, Scrinzi G, Scavone C, Capuano A, Radice S, et al. Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression. Eur Child Adol Psychiatry. 2020. https:\/\/doi.org\/10.1007\/s00787-020-01582-9.","journal-title":"Eur Child Adol Psychiatry."},{"key":"558_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","volume":"69","author":"P Whiting","year":"2016","unstructured":"Whiting P, Savovi\u0107 J, Higgins JP, Caldwell DM, Reeves BC, Shea B, Davies P, Kleijnen J, Churchill R. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225\u201334. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.06.005.","journal-title":"J Clin Epidemiol"},{"key":"558_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","volume":"66","author":"G Guyatt","year":"2013","unstructured":"Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2013;66:151\u20137. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.01.006.","journal-title":"J Clin Epidemiol."},{"key":"558_CR38","first-page":"184","volume":"4","author":"L Ruan","year":"2010","unstructured":"Ruan L, Hu S, Huang M, Hu J, Cai W. Efficacy and safety of long-acting risperidone on early onset schizophrenia in adolescent patients. Afr J Pharm Pharmacol. 2010;4:184\u201392.","journal-title":"Afr J Pharm Pharmacol"},{"key":"558_CR39","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40261-017-0555-7","volume":"37","author":"MF Ceylan","year":"2017","unstructured":"Ceylan MF, Erdogan B, Tural Hesapcioglu S, Cop E. Effectiveness, adverse effects and drug compliance of long-acting injectable risperidone in children and adolescents. Clin Drug Investig. 2017;37:947\u201356. https:\/\/doi.org\/10.1007\/s40261-017-0555-7.","journal-title":"Clin Drug Investig"},{"key":"558_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2021.102663","volume":"61","author":"P Jacob","year":"2021","unstructured":"Jacob P, Shere S, Kommu JVS. The use of first-generation long-acting injectable antipsychotics in children and adolescents-A retrospective audit from India. Asian J Psychiatr. 2021;61: 102663. https:\/\/doi.org\/10.1016\/j.ajp.2021.102663.","journal-title":"Asian J Psychiatr."},{"key":"558_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/cap.2018.0044","volume":"29","author":"D Petri\u0107","year":"2019","unstructured":"Petri\u0107 D, Ra\u010dki V, Ga\u010do N, Ka\u0161telan A, Graovac M. Retrospective analysis of the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients. J Child Adolesc Psychopharmacol. 2019;29:197\u2013204. https:\/\/doi.org\/10.1089\/cap.2018.0044.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"558_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajp.2017.02.024","volume":"27","author":"H Suzuki","year":"2017","unstructured":"Suzuki H, Hibino H, Inoue Y, Takaya A. Treatment retencion of risperidone long-acting injection in patients with early-onset schizophrenia in Japan. Asian J Psychiatry. 2017;27:137\u20138.","journal-title":"Asian J Psychiatry"},{"key":"558_CR43","first-page":"2","volume":"53","author":"A Aggarwal","year":"2021","unstructured":"Aggarwal A, Lindegaard V. Can a \u201cshot\u201d help prevent youth re-incarceration? Case report on use of a long-acting injectable antipsychotic in incarcerated youth. Psychopharm Bull. 2021;53:2.","journal-title":"Psychopharm Bull"},{"issue":"3","key":"558_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1089\/cap.2012.0121","volume":"23","author":"A Solfanelli","year":"2013","unstructured":"Solfanelli A, Curto M, Dimitri-Valente G, Kotzalidis GD, Gasperoni C, Sani G, et al. Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis. J Child Adolesc Psychopharmacol. 2013;23(3):232\u20134. https:\/\/doi.org\/10.1089\/cap.2012.0121.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"558_CR45","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.18295\/squmj.2018.18.02.014","volume":"18","author":"H Mirza","year":"2018","unstructured":"Mirza H, Harding D, Al-Balushi N. Paliperidone palmitate-induced delirium in an adolescent with schizophrenia: case report. Sultan Qaboos Univ Med J. 2018;18(2):e208\u201310. https:\/\/doi.org\/10.18295\/squmj.2018.18.02.014.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"558_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12240","author":"V Salvi","year":"2022","unstructured":"Salvi V, Appignanesi C, Marpepa B, Orsolini L, Volpe U. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacol Rep. 2022. https:\/\/doi.org\/10.1002\/npr2.12240.","journal-title":"Neuropsychopharmacol Rep."},{"key":"558_CR47","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/2045125315600141","volume":"5","author":"M F\u00e0brega","year":"2015","unstructured":"F\u00e0brega M, Sugranyes G, Baeza I. Two cases of long-acting paliperidone in adolescence. Ther Adv Psychopharmacol. 2015;5:304\u20136. https:\/\/doi.org\/10.1177\/2045125315600141.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"2","key":"558_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1039856218815744","volume":"27","author":"P McInnis","year":"2019","unstructured":"McInnis P, Kasinathan J. Combination long-acting injectable (LAI) antipsychotic medication in adolescents with severe psychosis and aggression: a case series. Australas Psychiatry. 2019;27(2):160\u20134. https:\/\/doi.org\/10.1177\/1039856218815744.","journal-title":"Australas Psychiatry"},{"key":"558_CR49","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/cap.2015.0091","volume":"26","author":"S Pope","year":"2016","unstructured":"Pope S, Zaraa SG. Efficacy of long-acting injectable antipsychotics in adolescents. J Child Adolesc Psychopharmacol. 2016;26:391\u20134. https:\/\/doi.org\/10.1089\/cap.2015.0091.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"558_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jpsychires.2020.06.013","volume":"129","author":"E Saucedo","year":"2020","unstructured":"Saucedo E, Carranza F, Guerrero AF, Garc\u00eda-Cervantes KI, \u00c1lvarez Villalobos NA, Acu\u00f1a VD, et al. Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis. J Psychiatr Res. 2020;129:222\u201333.","journal-title":"J Psychiatr Res"},{"key":"558_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/YIC.0000000000000310","volume":"35","author":"A Abdel-Baki","year":"2020","unstructured":"Abdel-Baki A, Medrano S, Maranda C, Ladouceur M, Tahir R, Stip E, et al. Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. Int Clin Psychopharmacol. 2020;35:221\u20138. https:\/\/doi.org\/10.1097\/YIC.0000000000000310.","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 1","key":"558_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-2007-979518","volume":"30","author":"B Ahrens","year":"1997","unstructured":"Ahrens B. Mortality studies and the effectiveness of drugs in long-term treatment. Pharmacopsychiatry. 1997;30(Suppl 1):57\u201361. https:\/\/doi.org\/10.1055\/s-2007-979518.","journal-title":"Pharmacopsychiatry"},{"key":"558_CR53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Meht\u00e4l\u00e4 J, Hoti F, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380. https:\/\/doi.org\/10.1016\/j.schres.2017.12.010.","journal-title":"Schizophr Res"},{"key":"558_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8810","volume":"4","author":"CY Huang","year":"2021","unstructured":"Huang CY, Fang SC, Shao YJ. Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Netw Open. 2021;4: e218810. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.8810.","journal-title":"JAMA Netw Open."},{"issue":"S7","key":"558_CR55","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.5694\/j.1326-5377.2007.tb01327.x","volume":"187","author":"PD McGorry","year":"2007","unstructured":"McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust. 2007;187(S7):S8-10. https:\/\/doi.org\/10.5694\/j.1326-5377.2007.tb01327.x.","journal-title":"Med J Aust"},{"key":"558_CR56","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1192\/bjp.bp.117.201475","volume":"211","author":"J Lally","year":"2017","unstructured":"Lally J, Ajnakina O, Stubbs B, Cullinane M, Murphy KC, Gaughran F, et al. Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. Br J Psychiatry. 2017;211:350\u20138. https:\/\/doi.org\/10.1192\/bjp.bp.117.201475.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"558_CR57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4088\/JCP.MY20096AH1C","volume":"82","author":"CU Correll","year":"2021","unstructured":"Correll CU, Howes OD. Treatment-resistant schizophrenia: definition, predictors, and therapy options. J Clin Psychiatry. 2021;82(5):96. https:\/\/doi.org\/10.4088\/JCP.MY20096AH1C.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 2","key":"558_CR58","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4103\/psychiatry.IndianJPsychiatry_556_18","volume":"61","author":"S Grover","year":"2019","unstructured":"Grover S, Avasthi A. Clinical Practice Guidelines for the management of schizophrenia in children and adolescents. Indian J Psychiatry. 2019;61(Suppl 2):277\u201393. https:\/\/doi.org\/10.4103\/psychiatry.IndianJPsychiatry_556_18.","journal-title":"Indian J Psychiatry."},{"key":"558_CR59","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatr. 2020;177:868\u201372. https:\/\/doi.org\/10.1176\/appi.ajp.2020.177901.","journal-title":"Am J Psychiatr"},{"key":"558_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.5498\/wjp.v11.i8.429","volume":"11","author":"S Chakrabarti","year":"2021","unstructured":"Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management. World J Psychiatry. 2021;11:429\u201348. https:\/\/doi.org\/10.5498\/wjp.v11.i8.429.","journal-title":"World J Psychiatry."},{"key":"558_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/YIC.0000000000000336","volume":"36","author":"AM Caliskan","year":"2021","unstructured":"Caliskan AM, Karaaslan M, Inanli I, Caliskan S, Arslan M, Esra Cicek I, et al. The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study. Int Clin Psychopharmacol. 2021;36:30\u20133. https:\/\/doi.org\/10.1097\/YIC.0000000000000336.","journal-title":"Int Clin Psychopharmacol"},{"key":"558_CR62","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2020.72","volume":"63","author":"M Bioque","year":"2020","unstructured":"Bioque M, Parellada E, Garc\u00eda-Rizo C, Amoretti S, Fortea A, Oriolo G, et al. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. Eur Psychiatry. 2020;63: e71. https:\/\/doi.org\/10.1192\/j.eurpsy.2020.72.","journal-title":"Eur Psychiatry."},{"issue":"191","key":"558_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"1","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;1(191):234\u201358. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.07.011.","journal-title":"Drug Alcohol Depend"},{"key":"558_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.eurpsy.2009.01.002","volume":"24","author":"G Sugranyes","year":"2009","unstructured":"Sugranyes G, Flamarique I, Parellada E, Baeza I, Goti J, Fernandez-Egea E, et al. Cannabis use and age of diagnosis of schizophrenia. Eur Psychiatry. 2009;24:282\u20136. https:\/\/doi.org\/10.1016\/j.eurpsy.2009.01.002.","journal-title":"Eur Psychiatry"},{"key":"558_CR65","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/0706743717720196","volume":"62","author":"D Crockford","year":"2017","unstructured":"Crockford D, Addington D. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry. 2017;62:624\u201334. https:\/\/doi.org\/10.1177\/0706743717720196.","journal-title":"Can J Psychiatry"},{"key":"558_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/eip.12826","volume":"14","author":"A Abdel-Baki","year":"2020","unstructured":"Abdel-Baki A, Thibault D, Medrano S, Stip E, Ladouceur M, Tahir R, et al. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. Early Interv Psychiatry. 2020;14:69\u201379. https:\/\/doi.org\/10.1111\/eip.12826.","journal-title":"Early Interv Psychiatry"},{"key":"558_CR67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.rpsm.2018.03.006","volume":"12","author":"C Arango","year":"2019","unstructured":"Arango C, Baeza I, Bernardo M, Ca\u00f1as F, de Dios C, D\u00edaz-Mars\u00e1 M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment (Engl Ed). 2019;12:92\u2013105. https:\/\/doi.org\/10.1016\/j.rpsm.2018.03.006.","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)."},{"key":"558_CR68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JCP.0000000000001322","volume":"41","author":"M Dinnissen","year":"2021","unstructured":"Dinnissen M, Dietrich A, van der Molen JH, Verhallen AM, Buiteveld Y. Guideline\u00a0adherence\u00a0of monitoring antipsychotic use for nonpsychotic indications in\u00a0children\u00a0and\u00a0adolescents: a\u00a0patient\u00a0record review. J Clin Psychopharmacol. 2021;41:13\u20138. https:\/\/doi.org\/10.1097\/JCP.0000000000001322.","journal-title":"J Clin Psychopharmacol."},{"key":"558_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1024\/1422-4917\/a000505","volume":"46","author":"A H\u00e4ge","year":"2018","unstructured":"H\u00e4ge A, Weymann L, Bliznak L, M\u00e4rker V, Mechler K, Dittmann RW. Non-adherence to psychotropic medication among adolescents\u2014a systematic review of the literature. Z Kinder Jugendpsychiatr Psychother. 2018;46:69\u201378. https:\/\/doi.org\/10.1024\/1422-4917\/a000505.","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"issue":"1","key":"558_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/JCP.0000000000000035","volume":"34","author":"S Molteni","year":"2014","unstructured":"Molteni S, Giaroli G, Rossi G, Comelli M, Rajendraprasad M, Balottin U. Drug attitude in adolescents: a key factor for a comprehensive assessment. J Clin Psychopharmacol. 2014;34(1):99\u2013108. https:\/\/doi.org\/10.1097\/JCP.0000000000000035.","journal-title":"J Clin Psychopharmacol"},{"key":"558_CR71","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.euroneuro.2015.04.003.Treatment","volume":"25","author":"P Czobor","year":"2015","unstructured":"Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015;25:1158\u201366. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.04.003.Treatment.","journal-title":"Eur Neuropsychopharmacol"},{"key":"558_CR72","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40263-016-0350-7","volume":"30","author":"E Parellada","year":"2016","unstructured":"Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30:689\u2013701. https:\/\/doi.org\/10.1007\/s40263-016-0350-7.","journal-title":"CNS Drugs"},{"key":"558_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00787-022-02104-5","volume":"21","author":"M Solerdelcoll","year":"2022","unstructured":"Solerdelcoll M, Ilzarbe D, Fortea A, Morer A, Lazaro L, Sugranyes G, Baeza I. Psychopathology and mental health service use among youth in foster care admitted to a psychiatric inpatient unit: a 4-year retrospective controlled study. Eur Child Adolesc Psychiatry. 2022;21:1\u201312. https:\/\/doi.org\/10.1007\/s00787-022-02104-5.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"5","key":"558_CR74","doi-asserted-by":"publisher","first-page":"202","DOI":"10.9740\/mhc.2018.09.202","volume":"8","author":"T Modesitt","year":"2018","unstructured":"Modesitt T, Kubascik E, Ott C. Extent of use of long-acting injectable antipsychotics in children and adolescents within Indiana Medicaid. Ment Health Clin. 2018;8(5):202\u20137. https:\/\/doi.org\/10.9740\/mhc.2018.09.202.","journal-title":"Ment Health Clin."},{"key":"558_CR75","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1017\/S0033291708004868","volume":"39","author":"M Parellada","year":"2009","unstructured":"Parellada M, Fraguas D, Bomb\u00edn I, Otero S, Castro-Fornieles J, Baeza I, et al. Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study. Psychol Med. 2009;39:1433\u201345. https:\/\/doi.org\/10.1017\/S0033291708004868.","journal-title":"Psychol Med"},{"key":"558_CR76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/schbul\/sbq109","volume":"37","author":"M Parellada","year":"2011","unstructured":"Parellada M, Boada L, Fraguas D, Reig S, Castro-Fornieles J, Moreno D, et al. Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: A 2-year longitudinal study. Schizophr Bull. 2011;37:38\u201351. https:\/\/doi.org\/10.1093\/schbul\/sbq109.","journal-title":"Schizophr Bull"},{"key":"558_CR77","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1176\/ajp.150.6.873","volume":"150","author":"XF Amador","year":"1993","unstructured":"Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993;150:873\u20139.","journal-title":"Am J Psychiatry"},{"key":"558_CR78","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/schbul\/sbm002","volume":"33","author":"TM Lincoln","year":"2007","unstructured":"Lincoln TM, L\u00fcllmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review Schizophr Bull. 2007;33:1324\u201342. https:\/\/doi.org\/10.1093\/schbul\/sbm002.","journal-title":"A systematic review. Schizophr Bull."},{"key":"558_CR79","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.comppsych.2007.08.001","volume":"49","author":"K Osatuke","year":"2008","unstructured":"Osatuke K, Ciesla J, Kasckow JW, Zisook S, Mohamed S. Insight in schizophrenia: a review of etiological models and supporting research. Compr Psychiatry. 2008;49:70\u20137. https:\/\/doi.org\/10.1016\/j.comppsych.2007.08.001.","journal-title":"Compr Psychiatry"},{"key":"558_CR80","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1017\/S0033291706007793","volume":"36","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS, et al. Insight in first-episode psychosis. Psychol Med. 2006;36:1385\u201393.","journal-title":"Psychol Med"},{"key":"558_CR81","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1176\/appi.ps.201800362","volume":"70","author":"J Hamann","year":"2019","unstructured":"Hamann J, Heres S. Why and how family caregivers should participate in shared decision making in mental health. Psychiatr Serv. 2019;70:418\u201321.","journal-title":"Psychiatr Serv"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00558-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-023-00558-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00558-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T19:04:46Z","timestamp":1676487886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-023-00558-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s40272-023-00558-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"8 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct this study or for the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"IB has received honoraria and travel support from Angelini, Otsuka-Lundbeck, and Janssen and grants from the Spanish Ministry of Health, Instituto de Salud Carlos III supported by ERDF\u00a0Funds\u00a0from the European Commission (PI18\/0242\/PI21\/0391). AF has received travel and educational support from Janssen Cilag and Otsuka-Lundbeck. DI has received continuing medical education support from Rubi\u00f3 and\u00a0Angelini. GS has received speaker fees from Angelini, and has received funding from the Alicia Koplowitz Foundation, the Brain and Behaviour Research Foundation and the Instituto de Salud Carlos III supported by ERDF\u00a0Funds\u00a0from the European Commission (PI1800976, PI21\/00330), the Catalonia Government (2017SGR881, PERIS SLT006\/17\/00346), and Fundaci\u00f3 Cl\u00ednic Recerca Biom\u00e8dica (Ajut a la Recerca Pons Bartran).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"IB had the idea for the article, IB and AF performed the literature search and extracted the information. All the authors contributed to the interpretation of the data for the work. The first draft of the manuscript was written by IB and all authors commented on previous versions of the manuscript. All authors have read and approved the final manuscript, and agreed to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}